PharmaShots Weekly Snapshot (April 08-12, 2019)

1.Omron Healthcare Receives FDA’s Approval for Complete a Blood Pressure Monitoring Device with ECG Facility

Published: April 12, 2019 | Tags: Omron Healthcare, Receives, FDA, Approval, Complete, Blood Pressure, Monitoring, Device, EKG, Facility

2.Gilead and Novo Nordisk Collaborate to Conduct a Combination Therapy Trial in NASH

Published: April 12, 2019 | Tags: Gilead, Novo Nordisk, Collaborate, Conduct, Combination Therapy, Trial, NASH

3. Moleculin Signs a Clinical Research Agreement with Emory University for Brain Tumor in Pediatric Patients

Published: April 12, 2019 | Tags: Moleculin, Signs, Clinical, Research, Agreement, Emory University, WP1066, Brain Tumor, Pediatric Patients

4. Evotec Signs a Research Agreement with Indivumed to Develop Precision Therapies for Colorectal Cancer (CRC)

Published: April 12, 2019 | Tags: Evotec, Sign, Research, Agreement, Indivumed, Develop, Precision, Therapies, Colorectal Cancer, CRC

5. Merck’s Keytruda (pembrolizumab) Receives FDA’s Expanded Monotherapy Label Approval for Patients with 1L Stage III Non-Small Cell Lung Cancer (NSCLC)

Published: April 12, 2019 | Tags: Merck, Keytruda, pembrolizumab, Receives, FDA, Expanded, Monotherapy, Label, Approval, Patients, 1L, Stage III, Non-Small Cell Lung Cancer, NSCLC

6. BioDelivery Sciences (BDSI) Signs a License Agreement with Shionogi to Commercialize Symproic (naldemedine) in the US

Published: April 11, 2019 | Tags: BioDelivery Sciences, BDSI, Signs, License, Agreement, Shionogi, Commercialize, Symproic, naldemedine, the US

7. Cognoa Signs an Exclusive License Agreement with Stanford for its Google Glass-based Technology for Children with Autism Spectrum Disorder (ASD)

Published: April 11, 2019 | Tags:Cognoa, Signs, Exclusive, License, Agreement, Stanford, Google Glass-based Technology, Children, Autism Spectrum Disorder, ASD

8.Sandoz Signs a Commercialization Agreement with Shionogi for Rizmoic (naldemedine) in Europe

Published: April 11, 2019 | Tags: Sandoz, Collaborates, Shionogi, Commercialize, Rizmoic, naldemedine

9. Shanghai Miracogen Signs a Non-Exclusive License Agreement with Synaffix for its ADC Technologies

Published: April 11, 2019 | Tags: Shanghai Miracogen, Signs, Non-Exclusive, License, Agreement, Synaffix, ADC Technologies

10. Astellas Collaborates with Concerto HealthAI on Real-World Evidence (RWE) Initiative for Acute Myeloid Leukemia (AML)

Published: April 11, 2019 | Tags: Astellas, Collaborates, Concerto HealthAI, Real-World Evidence, RWE, Initiative, Acute Myeloid Leukemia, AML

11.Shanghai Fosun Signs an Exclusive License Agreement with ReNeuron for its CTX and hRPC Cell Therapy in China

Published: April 10, 2019 | Tags: Shanghai Fosun, Signs, Exclusive, License, Agreement, ReNeuron, CTX, hRPC, Cell Therapy 

12. Alkermes’ Reports Results of Aristada (aripiprazole lauroxil) and Invega Sustenna (paliperidone palmitate) in P-IIIb ALPINE Study to Treat Schizophrenia

Published: April 10, 2019 | Tags: Alkermes, Reports, Results, Aristada, aripiprazole lauroxil, Invega Sustenna, paliperidone palmitate, P-IIIb, ALPINE Study, Treat, Schizophrenia

13. AstraZeneca and Merck’s Lynparza (olaparib) Receive EU’s Approval as a Monotherapy to Treat Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer

Published: April 10, 2019 | Tags: AstraZeneca, Merck, Lynparza, olaparib, Receives, EU, Approval, Monotherapy, Treat, Germline, BRCA-Mutated, HER2-Negative, Advanced, Breast Cancer

14. Xinhua Healthcare Signs an Exclusive License Agreement with ArcDia for its mariPOC Technology in China

Published: April 10, 2019 | Tags: Xinhua Healthcare, Signs, Exclusive, License, Agreement, ArcDia, mariPOC, technology, China

15. Amgen’s Evenity (romosozumab-aqqg) Receives FDA’s Approval for Osteoporosis in Postmenopausal Women at High Risk for Fracture

Published: April 10, 2019 | Tags: Amgen, Evenity, romosozumab-aqqg, Receives, FDA, Approval, Osteoporosis, Postmenopausal Women, High Risk, Fracture

16. BeiGene Signs a Worldwide Co-Development and Commercialization Agreement with BioAtla for BA3071 and Tislelizumab

Published: April 09, 2019 | Tags: BeiGene, Signs, Worldwide, Co-Development, Commercialization, Agreement, BioAtla, BA3071, Tislelizumab

17. Audentes Signs an Exclusive License Agreement with Nationwide Children’s Hospital (NCH) for the Expansion of its AAV Technology and Pipeline

Published: April 09, 2019 | Tags: Audentes, Collaborates, Nationwide Children’s Hospital, Expansion, AAV Technology, Pipeline

18. uniQure’s AMT-130 Receives FDA’s Fast Track Designation for Huntington’s Disease

Published: April 09, 2019 | Tags: uniQure, AMT-130, Receives, FDA, Fast Track Designation, Huntington’s Disease

19. ViiV Healthcare’s Dovato (dolutegravir/lamivudine) Receives FDA’s Approval to Treat HIV-1 Infection in Adults

Published: April 09, 2019 | Tags: GSK, Dovato, dolutegravir/lamivudine, Receives, FDA, Approval, Treat, HIV-1, infection, Adults

20.Regeneron Collaborates with Alnylam to Discover, Develop and Commercialize RNAi Therapeutics for Ophthalmic and CNS Disorders

Published: April 09, 2019 | Tags: Regeneron, Collaborates, Alnylam, Discover, Develop, Commercialize, RNAi Therapeutics, Ophthalmic, CNS Disorders

21. Xoma Purchases Royalty Rights for Aronora’s Five Preclinical and Clinical Hematology Candidates

Published: April 08, 2019 | Tags: Xoma, Purchases, Aronora, Royalty, Rights, Five, Hematology Candidates

22.Sanofi and Alnylam Exercise Research and Option Phase Collaboration for its 2014 Deal

Published: April 08, 2019 | Tags: Sanofi, Alnylam, Exercise, Research, Option, Phase, Collaboration, Rare Diseases, 2014

23.Celgene and Acceleron Pharma Submit Biologics License Application (BLA) to the US FDA for Luspatercept

Published: April 08, 2019 | Tags: Celgene, Acceleron, Submit, Biologics License Application, US FDA, Luspatercept

24. Avita Medical Reports Results of RECELL System in Investigational Device Exemption (IDE) Compassionate Use and Continued Access Studies for Third-Degree Burns in Pediatric Patients

Published: April 08, 2019 | Tags: AVITA Medical, Reports, Results, RECELL System, Investigational Device Exemption, IDE, Compassionate Use, Continued Access Studies, Third-Degree Burns, Pediatric Patients

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on

Related post